- Home
- PAYP vs AXSM Comparison
PAYP vs AXSM Comparison
Compare PAYP & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYP | AXSM |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.4B |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PAYP | AXSM |
|---|---|---|
| Price | $15.72 | $157.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 22 |
| Target Price | $24.13 | ★ $282.54 |
| AVG Volume (30 Days) | 532.0K | ★ 759.2K |
| Earning Date | 11-14-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.72 | $49.19 |
| Revenue Next Year | $18.06 | $59.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.07 | $123.50 |
| 52 Week High | $24.89 | $260.19 |
Technical Indicators
Market Signals| Indicator | PAYP | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 24.39 |
| Support Level | $14.57 | $152.83 |
| Resistance Level | $16.50 | $169.11 |
| Average True Range (ATR) | 0.51 | 6.50 |
| MACD | -0.06 | -1.45 |
| Stochastic Oscillator | 73.88 | 7.45 |
Price Performance
Historical ComparisonAbout PAYP PayPay Corporation American Depository Shares
PayPay is a financial technology company jointly owned by Softbank and LY. It was founded in 2018, following the success of Alipay and WeChat Pay in China, and was the pioneering code payment app in Japan. Over the past seven years, it has amassed more than 70 million users and is the market leader in code payments.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.